Related Experiment Video
Updated: Jun 24, 2025
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Seema Mustafa1, Caroline S Jansen1,2, Yash Jani3
1Emory University School of Medicine, Atlanta, GA, USA.
Abstract:
In the past decade, immune checkpoint inhibitors (ICI) have been approved for treatment of genitourinary malignancies and have revolutionized the treatment landscape of these tumors. However, despite the remarkable success of these therapies in some GU malignancies, many patients' tumors do not respond to these therapies, and others may experience significant side effects, such as immune-related adverse events (iRAEs). Accordingly, biomarkers and improved prognostic tools are critically needed to help predict which patients will respond to ICI, predict and mitigate risk of developing immune-related adverse events, and inform personalized choice of therapy for each patient. Ongoing clinical and preclinical studies continue to provide an increasingly robust understanding of the mechanisms of the response to immunotherapy, which continue to inform biomarker development and validation. Herein, we provide a comprehensive review of biomarkers of the response to immunotherapy in GU tumors and their role in selection of therapy and disease monitoring.
Insights
Immune checkpoint inhibitors (ICI) have transformed genitourinary cancer treatment, but patient response varies. Biomarkers are crucial for predicting response, managing side effects, and personalizing therapy for better outcomes.
Area of Science:
- Oncology
- Immunology
- Genitourinary Malignancies
Background:
- Immune checkpoint inhibitors (ICI) have revolutionized genitourinary (GU) cancer treatment.
- However, patient response to ICI therapy is inconsistent, with many experiencing limited efficacy or immune-related adverse events (iRAEs).
- There is a critical need for biomarkers to guide treatment decisions and improve patient outcomes.
Purpose of the Study:
- To provide a comprehensive review of biomarkers for predicting response to ICI in GU tumors.
- To discuss the role of these biomarkers in therapy selection and disease monitoring.
- To highlight the importance of biomarkers in personalizing cancer treatment.
Main Methods:
- Review of existing clinical and preclinical studies on immunotherapy biomarkers in GU malignancies.
- Analysis of mechanisms underlying response and resistance to ICI.
- Synthesis of current knowledge on biomarker development and validation.
Main Results:
- ICI therapy has shown significant success in certain GU malignancies.
- Numerous biomarkers are under investigation for predicting ICI response and iRAEs.
- Understanding immunotherapy mechanisms is key to advancing biomarker discovery.
Conclusions:
- Biomarkers are essential for optimizing ICI therapy in GU cancers.
- Predictive biomarkers will enable personalized treatment selection and improve patient stratification.
- Further research is needed to validate and implement these biomarkers in clinical practice for effective disease management.
